肾透明细胞癌合并多发性骨髓瘤1例并文献复习  

Clear cell renal cell carcinoma combined with multiple myeloma:A case report and literature review

作　　者：王家琪 孟建波[1] 宋晓宁[1] 张金巧[1] 藏美蓉 卢佳配 锁静 Wang Jiaqi;Meng Jianbo;Song Xiaoning;Zhang Jinqiao;Zang Meirong;Lu Jiapei;Suo Jing(Department of Hematology,Hebei Medical University Third Hospital,Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第三医院血液科,河北石家庄050000

出　　处：《临床荟萃》2024年第11期1021-1025,共5页Clinical Focus

摘　　要：目的探讨肾透明细胞癌合并多发性骨髓瘤的临床特点及共同治疗的基础及可能性。方法选取河北医科大学第三医院血液科住院患者1例,回顾性分析其临床资料。结果患者男性,52岁,右肾癌术后2.5年,出现腰痛,完善相关检查检验证实肾透明细胞癌合并多发性骨髓瘤,此例患者在制定多发性骨髓瘤治疗方案时兼顾了肾透明细胞癌的治疗,应用了含硼替佐米、来那度胺(沙利度胺的作用类似物和升级品)的诱导方案加来那度胺维持治疗,经治疗后,目前患者随访两种肿瘤病情稳定。结论肾透明细胞癌与多发性骨髓瘤有共同的致病通路,存在共同治疗的可能性。Objective To investigate the clinical features of clear cell renal cell carcinoma(ccRCC)combined with multiple myeloma(MM),and the basis and possibility of co-treatment.Methods The clinical data of one patient in the Hematology Department of Hebei Medical University Third Hospital were analyzed retrospectively.Results A 52-year-old male developed low back pain 2.5 years after the operation of ccRCC,and diagnosed as ccRCC combined with MM by a series examination.Treatment plan incorporated both ccRCC and MM.Induction regimen containing bortezomib and lenalidomide(analogs and upgraded versions of thalidomide)and maintenance therapy with lenalidomide were given,yielding a stable condition of both ccRCC and MM during the follow-up period.Conclusion ccRCC shares a common pathogenic pathway with MM.There may have a basis for the co-treatment of ccRCC and MM.

关 键 词：癌 肾细胞 多发性骨髓瘤 治疗 

分 类 号：R730.26[医药卫生—肿瘤] R733.3[医药卫生—临床医学]